This research investigates how the structure of comb polymers influences their ability to stabilize materials in applications ranging from fragrances and food products to wastewater treatment and drug delivery. By systematically modifying polymer architecture, the study identifies design rules that enable more effective, affordable, and targeted performance across diverse industrial and medical uses.

This research develops a method to deliver EGCG, a green tea compound known to break apart Alzheimer's-related protein tangles, into the brain. By chemically attaching EGCG to a carrier that can cross the brain's protective barrier, the project aims to create a potential therapeutic strategy for slowing memory loss and disease progression.

This research models blood flow in narrowed arteries and during catheterization using the Herschel–Bulkley fluid model. By simulating flow and drug dispersion, it identifies factors affecting unpredictability. These insights enable optimized treatments, improved medical device design, and better visualization for clinicians, ultimately enhancing safety and outcomes in cardiovascular care.

This research develops an inhalable treatment for lung infections using nanocrystalline silver with both antimicrobial and anti-inflammatory properties. By adapting proven skin-based technology for respiratory delivery via nebulization, it targets both pathogens and harmful inflammation, addressing a major gap in lung disease treatment affecting over a billion people worldwide.

This research develops smart, biodegradable bone scaffolds that guide regeneration in severe fractures. By delivering healing molecules directly to damaged tissue, the scaffolds promote stronger bone growth, reduce inflammation, and eliminate the need for repeated surgeries, enabling faster and more natural recovery in children.

This research explores an injectable, thermosensitive hydrogel to deliver plant-based anticancer drugs for cervical cancer. By stabilizing phytochemicals and enabling localized, controlled release, the hydrogel significantly improves tumor cell killing while reducing side effects, offering a more patient-centered and effective treatment strategy.

IBD patients have weakened gut microbes, leaving them with chronic inflammation and limited treatment options. This research engineers probiotic yeast with anchors, drug-carrying “backpacks,” and reprogrammed DNA to deliver targeted therapeutics safely and cheaply. Early results show these modified microbes could become effective, low-side-effect treatments for IBD and other gut diseases.

This project develops an “Aptamer Express,” a DNA-based Trojan horse designed to bypass the brain’s protective barriers, target tumours, and deliver cancer-killing drugs directly to brain cancer cells. The approach aims to overcome treatment resistance, improve precision, and reduce side effects, offering new hope for patients and their families.